| Verifiedfields | changed |
|---|---|
| Watchedfields | changed |
| Verifiedrevid | 451565418 |
| Iupac name | 1-[(5-Fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)methanone |
| Width | 180 |
| Legal br | F2 |
| Legal br comment | [1] |
| Legal ca | Schedule II |
| Legal de | Anlage II |
| Legal uk | Class B |
| Legal us | Schedule I |
| Legal nz | Temporary Class |
| Legal un | P II |
| Legal un comment | [2] |
| Cas number | 335161-24-5 |
| Pubchem | 53393997 |
| Kegg | C22771 |
| Chemspiderid | 24751884 |
| Unii | TBJ0966F1O |
| C | 24 |
| H | 22 |
| F | 1 |
| N | 1 |
| O | 1 |
| Smiles | O=C(C1=CN(CCCCCF)C2=C1C=CC=C2)C3=CC=CC4=C3C=CC=C4 |
| Stdinchi | 1S/C24H22FNO/c25-15-6-1-7-16-26-17-22(20-12-4-5-14-23(20)26)24(27)21-13-8-10-18-9-2-3-11-19(18)21/h2-5,8-14,17H,1,6-7,15-16H2 |
| Stdinchikey | ALQFAGFPQCBPED-UHFFFAOYSA-N |
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor.[3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.
Hazards
Convulsions have been reported[4] including at doses as low as 10 mg.[5]
Pharmacology
AM-2201 is a full agonist for cannabinoid receptors. Affinities are: with a Ki of 1.0 nM at CB1 and 2.6 nM at CB2.[6] The 4-methyl functional analog MAM-2201 probably has similar affinities.[original research?] AM-2201 has an EC50 of 38 nM for human CB1 receptors, and 58 nM for human CB2 receptors.[7] AM-2201 produces bradycardia and hypothermia in rats at doses of 0.3–3 mg/kg, comparable to the potency of JWH-018 in rats, suggesting potent cannabinoid-like activity.[7]
Pharmacokinetics
AM-2201 metabolism differs only slightly from that of JWH-018. AM-2201 N-dealkylation produces fluoropentane instead of pentane (or plain alkanes in general).[citation needed]
Detection
A forensic standard of AM-2201 is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[8]
Legal status
In the United States, AM-2201 is a Schedule I controlled substance.[9]
See also
References
- ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União. Archived 2023-08-27 at the Wayback Machine. Retrieved 2023-08-27.
- ^ "Substance Details AM-2201". Retrieved 2024-01-22.
- ^ Wilkinson SM, Banister, Kassiou M (2015). "Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids". Australian Journal of Chemistry. 68 (1): 4–8. doi:10.1071/CH14198
- ^ McQuade D, Hudson S, Dargan PI, Wood DM (March 2013). "First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201". European Journal of Clinical Pharmacology. 69 (3): 373–6. doi:10.1007/s00228-012-1379-2. PMID 22936123. S2CID 23136932
- ^ ekaJ (20 February 2011). "The Night I Killed My Friends". Erowid.org. Retrieved 11 June 2012.
- ^
- ^ Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407
- ^ "Southern Association of Forensic Scientists". Archived from the original on 2014-09-10. Retrieved 2013-07-16.
- ^ Controlled Substances listed by the DEA